Biophytis S.A.
BPTSY
Rank in Stocks
#33143
Biophytis S.A. is a clinical-stage biotechnology company dedicated to creating... Biophytis S.A. is a clinical-stage biotechnology company dedicated to creating therapies designed to mitigate age-related degenerative processes and enhance functional well-being for patients. The company's scientific approach centers on identifying and activating critical biological resilience pathways, aiming to protect against and counteract the diverse biological and environmental stressors that contribute to age-related diseases. Its primary drug candidate, Sarconeos (BIO101), is an orally administered small molecule currently in development for neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy (DMD). Sarconeos is also undergoing a Phase 2/3 clinical study investigating its potential to treat severe respiratory failure in individuals with COVID-19. Furthermore, Biophytis is advancing Macuneos (BIO201), another oral small molecule, for the management of retinal disorders including dry age-related macular degeneration (AMD) and Stargardt disease. The firm maintains a collaborative agreement with AFM-Telethon specifically for the development of Sarconeos (BIO101) in DMD. Founded in 2006, Biophytis S.A. is headquartered in Paris, France.
Share Price
$0.4
Last synced: 2026-11-19
Market Cap
$718.68K
Change (1 day)
0.00%
Change (1 year)
-80.00%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Biophytis S.A. (BPTSY)
Category
Healthcare
EPS for Biophytis S.A. (BPTSY)
EPS as of June 2025 TTM: $-9.78
According to Biophytis S.A.'s latest financial reports, its current EPS (TTM) is $-9.78. At the end of 2024 the company had an EPS of $-2.08, an increase over its 2023 EPS of $-138.74.
EPS history for Biophytis S.A. from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-9.78 | 370.28% |
| 2024 | $-2.08 | -98.50% |
| 2023 | $-138.74 | -76.93% |
| 2022 | $-601.34 | -49.94% |
| 2021 | $-1.20K | -42.79% |
| 2020 | $-2.10K | -58.51% |
| 2019 | $-5.06K | 3.91% |
| 2018 | $-4.87K | -21.72% |
| 2017 | $-6.22K | 11.52% |
| 2016 | $-5.58K | 17.85% |
| 2015 | $-4.73K | 672.65% |
| 2014 | $-612.72 | 19.61% |
| 2013 | $-512.25 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -260.09% |
US
|
|
| $-7.08 | -27.62% |
US
|
|
| $-5.29 | -45.92% |
AU
|
|
| $21.56 | -320.41% |
NL
|
|
| $12.73 | -230.16% |
BE
|
Questions about Biophytis S.A.'s earnings per share (EPS)
What is Biophytis S.A.'s earnings per share (EPS)?
Biophytis S.A.'s earnings per share (EPS) over the last twelve months is $-9.78, as of Jun 2025.
What was Biophytis S.A.'s earnings per share (EPS) in 2024?
In 2024, Biophytis S.A.'s earnings per share (EPS) was $-2.08, compared with $-138.74 in 2023.
How has Biophytis S.A.'s earnings per share (EPS) changed since 2019?
From 2019 to 2024, Biophytis S.A.'s earnings per share (EPS) was highest in 2024 ($-2.08) and lowest in 2019 ($-5.06K).
How does Biophytis S.A.'s earnings per share (EPS) compare with similar companies?
Biophytis S.A.'s earnings per share (EPS) ($-9.78) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.